DK3641753T3 - Bacitracin og/eller daptomycin kombineret med cannabidiol til behandling af bakterieinfektioner - Google Patents

Bacitracin og/eller daptomycin kombineret med cannabidiol til behandling af bakterieinfektioner Download PDF

Info

Publication number
DK3641753T3
DK3641753T3 DK18731456.2T DK18731456T DK3641753T3 DK 3641753 T3 DK3641753 T3 DK 3641753T3 DK 18731456 T DK18731456 T DK 18731456T DK 3641753 T3 DK3641753 T3 DK 3641753T3
Authority
DK
Denmark
Prior art keywords
daptomycin
cannabidiol
bacitracin
treatment
combined
Prior art date
Application number
DK18731456.2T
Other languages
English (en)
Inventor
Janne Kudsk Klitgaard
Claes Søndergaard Wassmann
Original Assignee
Univ Syddansk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Syddansk filed Critical Univ Syddansk
Application granted granted Critical
Publication of DK3641753T3 publication Critical patent/DK3641753T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK18731456.2T 2017-06-19 2018-06-19 Bacitracin og/eller daptomycin kombineret med cannabidiol til behandling af bakterieinfektioner DK3641753T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17176612 2017-06-19
PCT/EP2018/066234 WO2018234301A1 (en) 2017-06-19 2018-06-19 BACITRACIN AND / OR DAPTOMYCIN COMBINED WITH CANNABIDIOL FOR THE TREATMENT OF BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
DK3641753T3 true DK3641753T3 (da) 2022-12-12

Family

ID=59077951

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18731456.2T DK3641753T3 (da) 2017-06-19 2018-06-19 Bacitracin og/eller daptomycin kombineret med cannabidiol til behandling af bakterieinfektioner

Country Status (6)

Country Link
US (1) US11266609B2 (da)
EP (1) EP3641753B1 (da)
CA (1) CA3067542A1 (da)
DK (1) DK3641753T3 (da)
WO (1) WO2018234301A1 (da)
ZA (1) ZA201908447B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
WO2020000024A1 (en) * 2018-06-28 2020-01-02 Botanix Pharmaceuticals Ltd Antibacterial treatment using cannabinoid combinations
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
GB2581987B (en) * 2019-03-06 2021-11-17 Gw Res Ltd Use of cannabidiol in combination with antibiotics
WO2020194237A1 (en) * 2019-03-28 2020-10-01 Scicann Therapeutics Inc. Cannabinoid compositions and use thereof
AU2020270175A1 (en) * 2019-05-06 2021-12-02 The University Of British Columbia Antibiotic cannabinoid-terpene formulations
US20200376156A1 (en) * 2019-05-29 2020-12-03 Precision Biologics Methods of accelerating wound healing using cannabinoid compositions
CA3159405A1 (en) * 2019-11-29 2021-06-03 Matthew CALLAHAN Antibacterial treatment using a cannabinoid and an active agent
US20210330603A1 (en) * 2020-02-24 2021-10-28 The Reed Institute Methods of using cannabinoids for inhibiting induction of virulence in enteric pathogens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2431105A (en) 2005-10-12 2007-04-18 Gw Pharma Ltd Cannabinoids for the treatment of pulmonary disorders
WO2009158499A2 (en) 2008-06-25 2009-12-30 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US8784852B2 (en) * 2009-02-27 2014-07-22 Audrey Kunin Topical skin care composition
NL2006621C2 (en) 2011-04-18 2012-10-22 Fytagoras B V New medical use for acidic cannabinoids.
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
KR20230113404A (ko) 2012-05-09 2023-07-28 콘트라펙트 코포레이션 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의병용물
CN105764504A (zh) 2013-09-26 2016-07-13 罗纳德·D·塞库拉 引入大麻种衍生的植物药品的局部治疗
AU2015101908A4 (en) * 2014-12-21 2019-05-02 One World Cannabis Ltd Cannabis-based extracts and topical formulations for use in skin disorders
US10420815B2 (en) 2015-09-15 2019-09-24 The Governors Of The University Of Alberta Combinational therapy for synergistic inhibition of gram-positive and gram-negative bacteria
GB2542797A (en) 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
US20190374552A1 (en) * 2016-11-02 2019-12-12 George Edward Hoag Multifunctional formulations and methods to control dermatitis and pruritus

Also Published As

Publication number Publication date
EP3641753B1 (en) 2022-09-21
US20200146999A1 (en) 2020-05-14
US11266609B2 (en) 2022-03-08
EP3641753A1 (en) 2020-04-29
WO2018234301A1 (en) 2018-12-27
ZA201908447B (en) 2022-08-31
CA3067542A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
DK3641753T3 (da) Bacitracin og/eller daptomycin kombineret med cannabidiol til behandling af bakterieinfektioner
DK3681470T3 (da) Lactobacillus casei eller lactobacillus paracasei til anvendelse i behandling af clostridium difficile-infektioner
DK3349758T3 (da) Fremgangsmåder til behandling af arenaviridae-virusinfektioner
DK3474972T3 (da) Luftbehandlingssystemer og fremgangsmåder
IL273022A (en) Treatment of plant infections with mosaic viruses and bacteria
GB2554629B (en) Prevention and treatment of microbial infections
DK3687513T3 (da) Behandling af fragilt x-syndrom og autisme med cannabidiol
IL271863B (en) Compounds and their use for the treatment of microbial infections
IL263368A (en) Prevention and treatment of viral infections
DK3259515T3 (da) Fitting med coating, rørledningssystem og anvendelse af fittingen eller rørledningssystemet
EP3399995A4 (en) METHODS FOR PREVENTING AND TREATING PNEUMOCYSTIS INFECTIONS
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK3102218T3 (da) Behandling af topiske og systemiske bakterieinfektioner
DK3752506T3 (da) Pyrimidinderivater til forebyggelse og behandling af bakterielle infektioner
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
ZA202002069B (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
ZA201907487B (en) Compositions and treatment procedures for the treatment of pathogenic infections
SG11201809811VA (en) Compositions and methods for treatment of inflammation or infection of the eye
DK3476397T3 (da) Nye sammensætninger og deres anvendelse til behandling af bakterielle infektioner
DK3519411T3 (da) Heterocykliske forbindelser og deres anvendelse inden for forebyggelsen eller behandlingen af bakterieinfektioner
DK3197556T3 (da) Sammensætning til forebyggelse og/eller behandling af allergisymptomer
DK3432900T3 (da) Mælkesyrebakteriesammensæting til behandling af bakterielle vaginale infektioner forårsaget af gardnerella vaginalis og, hvis de forefindes, samtidige svampeinfektioner
CO2019014647A2 (es) Composiciones inmunogénicas
PL3658174T3 (pl) Laktoferycyna i laktoferampina do leczenia infekcji
IT201700086482A1 (it) Composizione per il trattamento della vaginosi batterica